Pyrotinib (SHR-1258)
HER2+ Breast Cancer
Key Facts
About Jiangsu Hengrui Medicine
Jiangsu Hengrui Medicine's mission is to advance healthcare through high-quality, innovative medicines, solidifying its position as China's largest and most valuable pharmaceutical company. Its key achievements include building a massive pipeline of 719 drug candidates, successfully launching multiple blockbuster oncology drugs in China, and establishing international R&D footprints. The company's strategy centers on aggressive investment in proprietary R&D, a dual-track approach of 'innovation + internationalization,' and dominating key therapeutic areas like oncology while expanding into metabolic, autoimmune, and neurological diseases.
View full company profileTherapeutic Areas
Other HER2+ Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| PYTX-004 | Papyrus Therapeutics | Preclinical |
| T-siHER2-NP™ | Pdx Pharmaceuticals | Preclinical |
| Biosimilar to Trastuzumab | Shenzhen Salubris Pharmaceuticals | Phase III |
| Phesgo® (with Roche) | Halozyme Therapeutics | Approved |
| Evorpacept + Trastuzumab + Chemotherapy (ASPEN-09) | ALX Oncology | Phase 1 |